3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
3
Completed
2
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Chondrosarcoma
1
Breast Neoplasms
1
Breast Cancer Metastatic
1
Interventions
X-Rays
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Magnetic Resonance Spectroscopy
4
regorafenib
3
Specimen Handling
3
Nivolumab
3
Cyclophosphamide
3
Biopsy
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
pembrolizumab
2
olaparib
2
larotrectinib
2
ivosidenib
2
fludarabine
2
ensartinib
2
cabozantinib
2
Etoposide
2
Docetaxel
2
tocilizumab
1
tazemetostat
1
poly ICLC
1
palbociclib
1
naxitamab
1
mifamurtide
1
humanized 3F8 anti-GD2 monoclonal antibody
1
glucarpidase
1
gamma-Glutamyl Hydrolase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Osteosarcoma
×
Zoledronic Acid
×
Clear all
NCT00470223
2025-06-08
OS2006
UNICANCER
Phase 3
Active not recruiting
318 enrolled